Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a G...

por Thill, Marc, Wimberger, Pauline, Grafe, Andrea, Klare, Peter, Luedtke-Heckenkamp, Kerstin, Reichert, Dietmar, Zaiss, Matthias, Ziegler-Löhr, Katja, Eckl, Tanja, Schneeweiss, Andreas
Publicado 2022

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

por Grote, Isabel, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko, zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva‐Maria, Schumacher, Claudia, Luedtke‐Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias, Kreipe, Hans
Publicado 2021